MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Core Insights - MiNK Therapeutics is set to present late-breaking data on AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, demonstrating durable clinical activity in advanced solid tumors at the upcoming SITC meeting [1][2] Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic iNKT cell therapies and precision immune modulators aimed at restoring immune balance and achieving durable cytotoxic responses [4] - The company's lead candidate, AgenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently undergoing clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure [5] - MiNK's pipeline includes TCR-based and neoantigen-targeted iNKT programs, which are designed for tissue-specific immune activation, showcasing a scalable manufacturing process and broad therapeutic potential [5]